Attention deficit hyperactive disorder(ADHD)
Conditions
Interventions
Measurement of DAT binding potential by using SPRCT
Diffusion tensor imaging with MRI
ERP
Sponsors
Fukushima Medical University
Janssen Pharmaceutical K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult ADHD patients; treatment-naive adult patients fulfilling the DSM5 criteria for ADHD. 2. ASD; treatment-naive adult patients fulfilling the DSM5 criteria for ASD. 3. Age and gender matched healthy subjects.
Exclusion criteria
Exclusion criteria: 1) No history of illicit drug use, antidepressants (at least not over the last3 months) or other psychoactive medication/medication affecting DAT (such as buproprion) in either patients or controls. 2) A history indicating excessive nicotine or alcohol intake (>0.5 packs of cigarettes, >4 glasses of an alcoholic substance a day). 3) Exclusion criteria to MRI: presence of a pacemaker, metallic implants in high-risk areas (i.e. vessel clips) and a history of claustrophobia. 4) Subjects during pregnancy and/or lacting.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. DAT BP in the striatum (putamen, caudate nucleus, and Nucleus Accumbens,:NAc,) measured by SPECT. 2. MMN measured by ERP 3. Parameters of brain network topology measured by DT-MRI | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical evaluation for ADHD and ASD (each test will be done in all subjects including controls) 1) Conners' Adult ADHD Rating Scales (CAARS) 2) The Adult Autism Spectrum Quotient (AQ) 2. Intelligence quotient with Wechsler Adult Intelligence Scale 3. Measurements of blood concentration of monoamine metabolites; HVA, tMHPG, fMHPG, 5-HIAA | — |
Countries
Japan
Contacts
Public ContactShuntaro Itagaki
Fukushima Medical University Neuropsychiatry
Outcome results
None listed